Cost-effectiveness of Crohn’s disease post-operative care

Table 2 Demographics n (%)

	Health economic sub-group	Entire POCER study cohort	P value
	n = 60	n = 174
n (male)	24 (40)	78 (45)	0.516
Age > 40 yr	24 (40)	68 (39)	0.900
Age, median	37	36
Age at diagnosis
≤ 16 yr	4 (7)	19 (11)	0.340
17-40 yr	49 (81)	134 (77)	0.451
> 40 yr	7 (12)	21 (12)	0.934
Duration of Crohn's disease ≥ 10 yr	29 (48)	60 (34)	0.154
Disease location at surgery:
Ileum only (L1)	33 (55)	95 (55)	0.957
Colon only (L2)	3 (5)	11 (6)	0.710
Ileum and colon (L3)	21 (35)	68 (39)	0.575
Disease phenotype at surgery:
B1 (Inflammatory)	5 (8)	17 (10)	0.742
B2 (Stricture)	18 (30)	62 (36)	0.428
B3 (Penetrating)	37 (62)	95 (55)	0.341
Indication for surgery:
Failure of drug therapy	12 (20)	38 (22)	0.764
Obstruction	14 (23)	50 (29)	0.418
Perforation	34 (57)	86 (49)	0.333
Number of prior surgical resections
0	47 (78)	124 (71)	0.287
1	9 (15)	33 (19)	0.490
2	1 (2)	9 (5)	0.247
3 or more	3 (5)	8 (5)	0.899
Active smoker	22 (37)	54 (31)	0.422
Immediate post-operative baseline drug therapy
Metronidazole alone	9 (15)	29 (17)	0.763
Thiopurine	39 (65)	101 (58)	0.343
Adalimumab	12 (20)	44 (25)	0.408
CDAI > 150	40 (67)	113 (65)	0.673
CDAI > 200	30 (50)	90 (52)	0.465